Business News

Roche Enters Drug Discovery Collaboration with Vividion Focused on Novel E3 Ligases

SAN DIEGO, May 19, 2020 /PRNewswire/ — Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY) to leverage its proteomics screening …

Read More »

Innovent Biologics and MD Anderson Partner to Develop anti-PD-1 Therapy Tyvyt in Rare Cancers

SUZHOU, China, and HOUSTON, May 18, 2020 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic …

Read More »

Janssen and Lava Therapeutics Collaborate to Develop Bi-Specific Gamma-Delta T-Cell Engager Therapeutics

UTRECHT, The Netherlands & PHILADELPHIA–(BUSINESS WIRE)–Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. …

Read More »

Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome

SALT LAKE CITY–(BUSINESS WIRE)–Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and develop it for the treatment of a hereditary cancer syndrome and related areas …

Read More »

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Ingelheim, Germany and Toronto, Canada – 14 May 2020 – Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology …

Read More »

Bayer and ArcherDX Announce Global Collaboration to Develop NGS-based Companion Diagnostic for Vitrakvi

BOULDER, Colo. & BERLIN–(BUSINESS WIRE)–Bayer and ArcherDX, Inc. today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for Vitrakvi® (larotrectinib). The primary objective of the collaboration is to broaden patient access to comprehensive genomic testing inclusive of neurotrophic receptor tyrosine kinase 1 …

Read More »

Skyhawk and Merck Expand Collaboration Agreement with to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

WALTHAM, Mass., May 12, 2020 /PRNewswire/ — Skyhawk Therapeutics, Inc. (“Skyhawk”) today announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing. Skyhawk’s proprietary SkySTARTM technology platform will be employed …

Read More »

Specifica Transfers Antibody Discovery Platform to Bayer

SANTA FE, N.M., May 12, 2020 /PRNewswire/ — Specifica, a leading provider of antibody discovery technologies, today announced the transfer of a suite of Specifica’s Generation 3 antibody libraries to Bayer under an agreement that will enable the development of antibody-based therapeutics. Antibody Libraries are the sources from which therapeutic …

Read More »

Novartis and Dyno Therapeutics Enter Ocular Collaboration to Develop Improved Gene Therapies with AAV Vectors based on AI Technology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a collaboration with Novartis to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. The partnership will allow the parties to utilize Dyno’s CapsidMap™ artificial intelligence …

Read More »

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to advance the field of human genetics and precision medicine through the sharing of 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in …

Read More »